Table 3.

Actual Antibiotic Use in Patients Treated with MRSA-Active Antibiotics

Variable	Brazil (n = 196)
Patient switched from IV to oral inpatient MRSA-active antibiotic treatment, n (%)	4 (2.0)
Days to MRSA targeted therapy, from cSSTI index date, n (%)
On or before cSSTI index	124 (63.3)
1–2 days post cSSTI index	29 (14.8)
3+ days post cSSTI index	43 (21.9)
Number of MRSA targeted courses of therapy, n (%)
1	161 (82.1)
2	33 (16.8)
3	2 (1.0)
MRSA active days of therapy (including PO), mean (SD)	14.7 (10.1)
MRSA active IV days, mean (SD)	14.6 (10.1)
MRSA targeted antibiotics used in initial line, n (%)
Vancomycin IV	114 (58.2)
Clindamycin IV	39 (19.9)
Daptomycin IV	13 (6.6)
TMP-SMX IV	7 (3.6)
Linezolid IV	6 (3.1)
Othera	17 (8.6)
MRSA targeted antibiotics used in last line, n (%)
Vancomycin IV	104 (53.1)
Clindamycin IV	28 (14.3)
Daptomycin IV	22 (11.2)
Linezolid IV	18 (9.2)
TMP-SMX IV	6 (3.1)
Otherb	18 (9.1)
Patient received targeted antibiotic at discharge, n (%)	31 (15.8)
Oral targeted therapy	25 (80.6)
MRSA-active antibiotics prescribed at discharge, n (%)	31 (15.8)
Clindamycin PO	13 (41.9)
Linezolid PO	5 (16.1)
TMP-SMX PO	3 (9.7)
Daptomycin IV	3 (9.7)
Vancomycin IV	2 (6.5)
Ciprofloxacin PO	2 (6.5)

Abbreviations: cSSTI, complicated skin and soft tissue infection; IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus; PO, oral; SD, standard deviation; TMP-SMX, trimethoprim/sulfamethoxazole.

^aOther includes: cefuroxime IV, ciprofloxacin IV + clindamycin IV, clindamycin IV, clindamycin IV + linezolid IV, clindamycin IV + TMP-SMX IV, clindamycin PO, daptomycin IV, doxycycline PO, linezolid IV, oxacillin IV, TMP-SMX IV, teicoplanin IV, teicoplanin IV + tigecycline IV, tigecycline IV, trimethoprim IV.

^bOther includes: ciprofloxacin IV, linezolid PO, oxacillin IV, piperacillin/tazobactam IV, TMP-SMX PO, teicoplanin IM, teicoplanin IV, tigecycline IV.